LavandeiraA. Orphan drugs: Legal aspects, current situation. Haemophilia, 2002; 8:194–198.
2.
The official website of the Nobel Prize.NobelPrize.org
3.
MarshallE. Gene therapy death prompts review of adenovirus vector. Science, 1999; 286:2244–2245.
4.
LiuLX, JanvierK, Berteaux-LecellierV, et al.Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters. J Biol Chem, 1999; 274:32738–32743.
5.
AubourgP. X-linked adrenoleukodystrophy. Ann Endocrinol, 2007; 68:403–411.
6.
PubMed search using precise term “Diagnostic Odyssey” performed November 12, 2015.
7.
BenhamidaS, PflumioF, Dubart-KupperschmittA, et al.Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Mol Ther, 2003; 7:317–324.
8.
Global Genes.. Must-have collaborations for successful drug development: Uniting patients and caregivers, researchers, industry, and government regulators at the table. A white paper expanding the panel discussion at the Global Genes Third Annual RARE Patient Advocacy Summit. March2015.
9.
CalongeN, GreenNS, RinaldoP, et al., Advisory Committee on Heritable Disorders in Newborns and Children. Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children. Genet Med, 2010; 12:153–159.
10.
TherrellBLJr.U.S. newborn screening policy dilemmas for the twenty-first century. Mol Genet Metab, 2001; 74:64–74.
Anna Grantham Hunter's Hope Foundation.. Family Advocates for Newborn Screening. http://rareadvocates.org/wp-content/uploads/2014/03/Family-Advocates-for-Newborn-Screening.pdf
13.
ALD Connect.. Doctor Patient Webinar Series. www.aldconnect.org/webinars.php
14.
CartierN, et al.Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 2009; 326:818–823.
